

## Preparation and Alkylation of *N*-*t*-Butyldimethylsilyl-3-trimethylsilyloxyazetidin-2-one

Roland E. Dolle,<sup>\*a</sup> Mark J. Hughes,<sup>b</sup> Chun-Sing Li,<sup>a</sup> and Lawrence I. Kruse<sup>a</sup>

<sup>a</sup> Department of Medicinal Chemistry,

<sup>b</sup> Department of Synthetic and Isotope Chemistry, Smith Kline & French Research Limited, The Frythe, Welwyn, Hertfordshire AL6 9AR, U.K.

The title  $\beta$ -lactam (**6**) is prepared in three steps from commercially available 2-azetidinone (**9**) (50% overall yield) and can be efficiently alkylated with a variety of electrophiles.

The lethal chlorotic action of tabtoxinine- $\beta$ -lactam (**1**),<sup>1</sup> the active constituent of tabtoxin<sup>1,2</sup> (wildfire toxin) is a well established consequence of the potent and irreversible inactivation of glutamine synthetase (GS).<sup>2,3</sup> Utilizing glutamate, ammonia, and ATP as substrates, GS initially phosphorylates glutamate affording an enzyme bound carboxylate-phosphate anhydride (**2**).<sup>3</sup> Nucleophilic attack by enzyme bound ammonia on (**2**) presumably gives rise to a tetrahedral intermediate (**3**) which subsequently collapses liberating glutamine, P<sub>i</sub>, and ADP. The 3-hydroxy-azetidin-2-one unit in (**1**) represents an efficient carboxylate mimic and when engaged with the enzyme, (**1**) is phosphorylated yielding a tightly bound analogue (**4**) [or (**5**)] of the acyl-phosphate intermediate.<sup>1</sup> By analogy with GS, other pharmacologically significant enzymes, which act as carboxylate kinases, may potentially be inactivated through thoughtful design of modified substrates incorporating this 3-hydroxy- $\beta$ -lactam unit.<sup>4</sup> Direct introduc-





Figure 1



**Scheme 1.** Reagents and conditions: i, see ref. 6; ii, LDA,  $-78^{\circ}\text{C}$ , then MoOPH; iii, Me<sub>3</sub>SiCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; iv, LDA,  $-78^{\circ}\text{C}$  then 1.5 equiv. electrophile,  $-78 \rightarrow 0^{\circ}\text{C}$ , Table 1; v, 9:1 MeOH, HOAc; vi, Bu<sub>4</sub>NF; HOAc, THF.

tion of such a structural unit would therefore be most useful.<sup>4,5,6</sup> As a general solution to this problem, we investigated the synthesis and alkylation of *N*-*t*-butyl-dimethylsilyl-3-trimethylsilyloxyazetidin-2-one (6) and herein report the utility of (6) as a 3-hydroxy- $\beta$ -lactam enolate equivalent (7).

*N*-*t*-Butyldimethylsilylazetidin-2-one (8) was prepared as previously described<sup>6</sup> from commercially available (Aldrich) 2-azetidinone (9) (78% yield; Scheme 1). Deprotonation of  $\beta$ -lactam (8) [1.2 equiv. lithium di-isopropylamide (LDA), tetrahydrofuran (THF),  $-78^{\circ}\text{C}$ , 30 min] and hydroxylation with the Vedejs molybdenum peroxide reagent MoOPH<sup>7</sup> (1.5 equiv.,  $-78 \rightarrow 25^{\circ}\text{C}$ , 30 min) gave 3-hydroxy- $\beta$ -lactam (10) as a white solid<sup>†</sup> [68%; m.p.  $52\text{--}55^{\circ}\text{C}$ ; <sup>1</sup>H n.m.r. (CDCl<sub>3</sub>)  $\delta$  4.95 (m, H-3), 3.49 (t, *J* 5.5 Hz, H-4), 3.19 (dd, *J* 5.5, 2.5 Hz, H-4')]. Treating (10) with chlorotrimethylsilane‡ (1.2 equiv. Me<sub>3</sub>SiCl, 1.5 equiv. Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>,  $25^{\circ}\text{C}$ , 1 h) afforded the title  $\beta$ -lactam (6) [97%, b.p.  $150^{\circ}\text{C}$  (Kugelrohr, 1.0 mmHg); <sup>1</sup>H n.m.r. (CDCl<sub>3</sub>)  $\delta$  4.88 (dd, *J* 5.2, 2.5 Hz, H-3)].

Alkylation of  $\beta$ -lactam (6) proved straightforward. Thus, deprotonation of (6) using LDA (1.1 equiv., THF,  $-78^{\circ}\text{C}$ , 30 min) was adequate to generate the colourless anion which upon addition of MeI (1.5 equiv.,  $-78^{\circ}\text{C} \rightarrow 0^{\circ}\text{C}$ , 30 min) provided *C*-methylated  $\beta$ -lactam (11a) (73%, Scheme 1, Table 1). The lithium anion derived from (6) reacted with other electrophiles including other alkyl halides, aldehydes, and Michael acceptors to give  $\beta$ -lactams (11b) through (11g) in 50–85% isolated yields (Table 1). Sequential removal of the silyl protecting groups in  $\beta$ -lactams (11a–11g) was accomplished [e.g., (11a)  $\rightarrow$  (13); 70%; Scheme 1] by mild acid treatment (1:9 HOAc  $\cdots$  MeOH,  $25^{\circ}\text{C}$ , 12 h; *O*-desilylation) followed by fluoride anion (1.2 equiv. each Bu<sub>4</sub>NF and HOAc,  $25^{\circ}\text{C}$ , 15 min; *N*-desilylation). Simultaneous fluoride mediated *N*- and *O*-desilylation was also possible [2.5 equiv. each Bu<sub>4</sub>NF and HOAc,  $25^{\circ}\text{C}$ , 15 min; (11a)  $\rightarrow$  (13); 90%].‡

Application of this chemistry to the design and synthesis of novel enzyme inhibitors will be forthcoming.

One of us (C-S. L.) is a postdoctoral fellow at Smith Kline & French.

**Table 1.** Reaction of the lithium enolate of (6) with selected electrophiles.

Electrophile <sup>a</sup>	Product	% Yield <sup>b</sup>
MeI	(11a)	73
CH <sub>2</sub> CHCH <sub>2</sub> Br	(11b)	85
CH <sub>2</sub> CHCH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> Br	(11c)	52
Bu <sup>t</sup> Me <sub>2</sub> SiOCH <sub>2</sub> CH <sub>2</sub> I	(11d)	83
CH <sub>2</sub> CHCH <sub>2</sub> CH <sub>2</sub> I	(11e)	72
PhCHO	(11f)	65
CH <sub>2</sub> C(Me <sub>3</sub> Si)CO <sub>2</sub> CH <sub>2</sub> Ph	(11g)	70 <sup>c</sup>

<sup>a</sup> Anion reacted with 1.5 equiv. of the electrophile, see text. <sup>b</sup> Isolated yield. <sup>c</sup> 3:1 mixture of diastereoisomers.

† All new compounds exhibited physical and spectroscopic properties consistent with their structure.

‡ 3-Hydroxyazetidin-2-one (10) reacted with PhCH<sub>2</sub>OCH<sub>2</sub>Cl under standard conditions affording the corresponding 3-benzyloxymethyl ether (68%). This ether was alkylated with MeI (64%). Use of this protecting group permits sequential *N*- then *O*-deprotection.

Received, 31st May 1989; Com. 9/02270H

## References

- W. W. Stewart, *Nature*, 1971, **229**, 174; T. F. Uchtyl and R. D. Durbin, *Experientia*, 1980, **36**, 301.
- S. L. Sinden and R. D. Durbin, *Nature*, 1968, **219**, 379; C. J. Unkefer, R. E. London, R. D. Durbin, T. F. Uchtyl, and P. J. Langston-Unkefer, *J. Biol. Chem.*, 1987, **262**, 4994.
- T. D. Meek and J. V. Villafranca, *Biochemistry*, 1980, **19**, 5513.
- W. J. Greenlee, J. P. Springer, and A. A. Patchett, *J. Med. Chem.*, 1989, **32**, 165.
- For the construction of the 3-hydroxy- $\beta$ -lactam unit in the context of the total synthesis of taboxin and tabtoxine- $\beta$ -lactam see: J. E. Baldwin, M. Otsuka, and P. M. Wallace, *Tetrahedron*, 1986, **42**, 3097; *J. Chem. Soc., Chem. Commun.*, 1985, 1549; J. E. Baldwin, P. D. Bailey, G. Gallacher, M. Otsuka, K. A. Singleton, P. M. Wallace, K. Prout, and W. M. Wolf, *Tetrahedron*, 1984, **40**, 3695; J. E. Baldwin, P. D. Bailey, G. Gallacher, M. Otsuka, K. A. Singleton, and P. M. Wallace, *J. Chem. Soc., Chem. Commun.*, 1983, 1049; D. L. Lee and H. Rapoport, *J. Org. Chem.*, 1975, **40**, 3491.
- W. W. Ogilvie and T. Durst, *Can. J. Chem.*, 1988, **66**, 304.
- A. T. Daniewski and W. Wojciechowska, *Synth. Commun.*, 1986, **16**, 535; E. J. Vedejs, *J. Am. Chem. Soc.*, 1974, **96**, 5944.